Literature DB >> 27076220

Early vascular healing after titanium-nitride-oxide-coated stent versus platinum-chromium everolimus-eluting stent implantation in patients with acute coronary syndrome.

Ville Varho1, Tuomas O Kiviniemi2, Wail Nammas2, Jussi Sia3, Hannu Romppanen4, Mikko Pietilä2, Juhani K Airaksinen2, Jussi Mikkelsson5, Petri Tuomainen5, Anssi Perälä4, Pasi P Karjalainen5.   

Abstract

Data on early vascular healing response of novel stent designs are scarce. In this randomized prospective trial, we sought to compare early neointimal coverage of cobalt-chromium-based titanium-nitride-oxide-coated bioactive stents (CoCr-BAS) versus platinum-chromium everolimus-eluting stents (PtCr-EES) at 2-month follow-up in patients with acute coronary syndrome (ACS). Forty patients with ACS were randomized to receive either CoCr-BAS (n = 19) or PtCr-EES (n = 21). Neointimal strut coverage and strut apposition were examined by optical coherence tomography; and coronary flow reserve (CFR), fractional flow reserve (FFR) and index of microcirculatory resistance (IMR) were assessed using a coronary pressure wire at 2 months. Two patients in the PtCr-EES underwent OCT out of the time frame of the study, and were excluded from analysis. At 63 ± 8 days, 302 cross-sections (3412 struts) were analysed in the CoCr-BAS group, and 324 cross-sections (3460 struts) in the PtCr-EES group. Median [IQR] neointimal thickness was 203 [108] µm and 42.2 [41] µm for CoCr-BAS and PtCr-EES, respectively (p < 0.001). Median [IQR] percentage of uncovered struts was 1.2 [2.8] % versus 11.3 [17.7] %, respectively (p < 0.001). Flow measurements were comparable between the two groups (p > 0.05 for all). CoCr-BAS showed earlier and more adequate neointimal coverage of struts at 2 months, compared with PtCr-EES, but with more neointimal hyperplasia. Functional healing as assessed by CFR, FFR, and IMR was similar between the two stent arms.

Entities:  

Keywords:  Bioactive stent; Coronary flow reserve; Drug-eluting stent; Neointimal hyperplasia; Optical coherence tomography

Mesh:

Substances:

Year:  2016        PMID: 27076220     DOI: 10.1007/s10554-016-0871-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  34 in total

1.  Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry.

Authors:  Pasi P Karjalainen; Antti Ylitalo; Juhani Ke Airaksinen; Wail Nammas
Journal:  J Interv Cardiol       Date:  2010-10-06       Impact factor: 2.279

2.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

Authors:  Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2006-05-05       Impact factor: 24.094

3.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Christian W Hamm; Jean-Pierre Bassand; Stefan Agewall; Jeroen Bax; Eric Boersma; Hector Bueno; Pio Caso; Dariusz Dudek; Stephan Gielen; Kurt Huber; Magnus Ohman; Mark C Petrie; Frank Sonntag; Miguel Sousa Uva; Robert F Storey; William Wijns; Doron Zahger
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

4.  Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study.

Authors:  Francesco Prati; Enrico Romagnoli; Marco Valgimigli; Francesco Burzotta; Mauro De Benedictis; Angelo Ramondo; Roxana Mehran; Pieter R Stella
Journal:  Int J Cardiol       Date:  2014-08-13       Impact factor: 4.164

5.  Impact of different stent alloys on human vascular response to everolimus-eluting stent: an optical coherence tomography study: the OCTEVEREST.

Authors:  Giulio Guagliumi; Davide Capodanno; Hideyuki Ikejima; Hiram G Bezerra; Vasile Sirbu; Giuseppe Musumeci; Luigi Fiocca; Nikoloz Lortkipanidze; Angelina Vassileva; Satoko Tahara; Orazio Valsecchi; Marco A Costa
Journal:  Catheter Cardiovasc Interv       Date:  2012-05-02       Impact factor: 2.692

6.  A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.

Authors:  Gregg W Stone; Paul S Teirstein; Ian T Meredith; Bruno Farah; Christophe L Dubois; Robert L Feldman; Joseph Dens; Nobuhisa Hagiwara; Dominic J Allocco; Keith D Dawkins
Journal:  J Am Coll Cardiol       Date:  2011-04-04       Impact factor: 24.094

7.  Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.

Authors:  Seunghwan Kim; Jung-Sun Kim; Dong-Ho Shin; Byeong-Keuk Kim; Young-Guk Ko; Donghoon Choi; Yun-Kyeong Cho; Chang-Wook Nam; Seung-Ho Hur; Yangsoo Jang; Myeong-Ki Hong
Journal:  Am J Cardiol       Date:  2012-10-02       Impact factor: 2.778

8.  Dipyridamole coronary flow reserve stratifies prognosis in acute coronary syndrome patients without left anterior descending disease.

Authors:  Luigi Ascione; Guido Carlomagno; Chiara Sordelli; Raffaele Iengo; Vittorio Monda; Sergio Severino; Raffaele Merenda; Antonello D'Andrea; Pio Caso
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2013-01-02       Impact factor: 6.875

9.  Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.

Authors:  Sigmund Silber; Ajay J Kirtane; Jorge A Belardi; Minglei Liu; Sandeep Brar; Martin Rothman; Stephan Windecker
Journal:  Eur Heart J       Date:  2014-02-07       Impact factor: 29.983

10.  Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Authors:  Sripal Bangalore; Sunil Kumar; Mario Fusaro; Nicholas Amoroso; Michael J Attubato; Frederick Feit; Deepak L Bhatt; James Slater
Journal:  Circulation       Date:  2012-05-14       Impact factor: 29.690

View more
  5 in total

1.  Comparable neointimal healing in patients with stable coronary lesions and acute coronary syndrome: 3-month optical coherence tomography analysis.

Authors:  Yuma Hamanaka; Yohei Sotomi; Tomoaki Kobayashi; Takashi Omatsu; Jouke Dijkstra; Yasushi Sakata; Atsushi Hirayama; Akio Hirata; Yoshiharu Higuchi
Journal:  Int J Cardiovasc Imaging       Date:  2021-02-16       Impact factor: 2.357

2.  The Effect of Placing Flow-Diverting Stents in Intracranial Collateral Arteries of Miniature Pig.

Authors:  Jiwei Wang; Yanan Ding; Qiuxia Wang; Yanan Wang; Shiqing Mu; Lixin Bi; Youxiang Li
Journal:  Med Sci Monit       Date:  2017-03-23

Review 3.  Surface engineering and the application of laser-based processes to stents - A review of the latest development.

Authors:  J Dong; M Pacella; Y Liu; L Zhao
Journal:  Bioact Mater       Date:  2021-08-28

4.  Biological effect of microengineered grooved stents on strut healing: a randomised OCT-based comparative study in humans.

Authors:  Boris Vesga; Hector Hernandez; Sergio Higuera; Pawel Gasior; Dario Echeveri; Juan A Delgado; Antonio Dager; Camilo Arana; Charles Simonton; Akiko Maehara; Julio Palmaz; Juan F Granada
Journal:  Open Heart       Date:  2017-05-22

5.  Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study.

Authors:  Tomasz Roleder; Elvin Kedhi; Balazs Berta; Pawel Gasior; Wojciech Wanha; Magda Roleder; Joanna Fluder; Grzegorz Smolka; Andrzej Ochala; Wojciech Wojakowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-06-26       Impact factor: 1.426

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.